Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.
Gift Nifty was trading around 23,710 level, a premium of nearly 20 points from the Nifty futures’ previous close, indicating ...
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...
1h
Hosted on MSNWe Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Andy Reid is a three-time Super Bowl champion, potentially looking to add some more hardware to the mantle to conclude this ...
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results